Category

• Pipeline2

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• AMD2
• Geographic Atrophy2
• Clinical Trials1
• Retina1

• Organizations: Lineage Cell Therapeutics, Inc✕

Clear all

Pipeline

OpRegen phase 1/2a trial data shows promise for GA

OpRegen RPE cell therapy is being developed and marketed through a global collaboration with Lineage Cell Therapeutics, Roche, and Regeneron.

Pipeline

Lineage launches phase 2a study by Genentech for GA secondary to AMD

With no current FDA-approved therapies for geographic atrophy secondary to AMD, RG6501 (OpRegen) could be a game-changer for patients.